- Home
- UVV vs LTGO Comparison
UVV vs LTGO Comparison
Compare UVV & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UVV | LTGO |
|---|---|---|
| Founded | 1886 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1994 | 2026 |
Fundamental Metrics
Financial Performance| Metric | UVV | LTGO |
|---|---|---|
| Price | $45.62 | $22.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 302.5K | ★ 367.7K |
| Earning Date | 05-28-2026 | N/A |
| Dividend Yield | ★ 6.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,885,078,000.00 | N/A |
| Revenue This Year | $0.67 | N/A |
| Revenue Next Year | $0.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $43.36 | $17.22 |
| 52 Week High | $59.38 | $22.90 |
Technical Indicators
Market Signals| Indicator | UVV | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 33.10 | 82.56 |
| Support Level | $43.36 | $18.46 |
| Resistance Level | $54.26 | N/A |
| Average True Range (ATR) | 1.45 | 1.52 |
| MACD | -0.23 | 0.38 |
| Stochastic Oscillator | 20.38 | 62.98 |
Price Performance
Historical ComparisonAbout UVV Universal Corporation
Universal Corp is an international leaf tobacco supplier. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Tobacco Operations segment involves procuring and processing flue-cured, burley, dark air-cured, and oriental leaf tobacco for manufacturers of consumer tobacco products and performing related services. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, the Philippines, Germany, and Other Countries, with the majority of revenue from the USA.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.